Anthropic, OpenAI, and Stripe invest $500 million to eradicate respiratory infections.

According to CryptoWorld, Anthropic, OpenAI, and Stripe have jointly launched the Intercept consortium, announcing a $500 million investment to develop new antiviral drugs and promote air purification technology. The initiative is co-led by Nan Ransohoff, Stripe's Head of Public Goods, with contributors including Flu Lab, employees of the Jane Street exchange, and Bill Gates' philanthropic arm. The Intercept program will support the development of broad-spectrum vaccines and drugs for respiratory viruses such as the common cold, COVID-19, and influenza, with follow-up development handled by major pharmaceutical companies. Simultaneously, it plans to promote existing air purification technologies and build a network of potential buyers, including JPMorgan Chase, Mastercard, and Meta. Respiratory infections impose a significant burden on global public health; estimates suggest that the COVID-19 pandemic claimed approximately 14.9 million lives in 2020 and 2021, and research by the UK's Institute for Health Economics indicates that respiratory infections cost UK businesses approximately £44 billion annually.